



Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #70-24) 10/02/2024 Eiger
Biopharmaceuticals, Inc (EIGRO)

Notice has been received that the above Company's Amended Combined Disclosure Statement and Chapter 11 Plan became effective on 09/30/2024. Pursuant to the plan, On the Effective Date, Except to the extent the Holder of an Existing Equity Interest agrees to less favorable treatment, each Holder of an Existing Equity Interest shall receive, in full and final satisfaction, settlement, release, and discharge of such Interest, its pro rata share of the Existing Equity Interest Recovery Pool. Please consult the company's Joint Plan of Liquidation for further details.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Market Operations- 1-866-776-0800.

¹ See e.g., In re: Eiger Biopharmaceuticals, Inc., et al. Debtors. Chapter 11 Case No. 24-80040 (SGJ) (Jointly Administered) Fifth Amended Joint Plan of Liquidation of Eiger Biopharmaceuticals, Inc and Its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code.